Pulse Biosciences' Shoots For US Clearance Of Nano-Pulse Platform

Pulse Biosciences' nano-pulse technology, PulseTx, precisely targets and kills cells with short electrical pulses that induce cell death and induce an immunogenic response. The company has submitted a 510(k) application to the US FDA for the technology, seeking a broad soft-tissue ablation indication, but it is developing PulseTx for immunoncology and dermatology indication.

Series of images showing different stages of destruction of a tumor cell. 3D illustration. Can be used to illustrate effect of drugs, medicines, microbes, nanoparticles
• Source: Shutterstock

Pulse Biosciences Inc. expects to begin a pilot study of its PulseTx nano-pulse system for immunoncology applications within a year, building on preclinical research showing that very short pulses of electricity can both induce cell death without residual tissue damage and induce an immunologic response that prevents cancer from coming back.

"I think the year ahead was really about clinical development," Darrin Uecker, CEO and president of Pulse Biosciences, told Medtech Insight. "We spent the last 12 to 18 months...

More from Oncology

More from Device Area